

RHINOMED COMPLETES A\$6 MILLION CAPITAL RAISING

TOPLINE

- **Rhinomed raises A\$6.0 million via a placement at A\$0.22 per share**
- **Placement supported by multiple new institutional investors and existing shareholders**
- **Capital raising will support new product roll out and significant growth in sales and store rollout across the US, Europe and Australia.**

September 23rd, 2019. Melbourne. Australian and New York, USA

Rhinomed (ASX:RNO, OTCQB:RHNMF) a global leader in nasal technology and the developers of Mute™, Turbine™, and Pronto™ is pleased to announce that it has successfully completed a placement of \$6.0 million to institutional and sophisticated investors at \$0.22 per share.

Funds raised under the capital raising will drive accelerated sales growth through current products, new product launches and significant store growth.

Commenting on the Placement, Mr Ron Dewhurst, Chairman stated *'On behalf of the Board, we are delighted with the very positive response to this capital raising. We are pleased to welcome multiple new institutional investors onto the register and appreciate the ongoing support from existing shareholders. The level of support speaks to the strong commercial opportunity and global potential of our proprietary platform technology and growing global distribution network.'*

The placement is priced at \$0.22 per new share, which represents an 8.3% discount to the closing share price on 18 September, the last business day on which the company's shares traded prior to this announcement. The offer price represents a 6.6% discount to the 5 day VWAP. All new placement shares will rank equally with the existing shares. The Placement Shares will be issued under the Company's existing capacity under ASX Listing Rule 7.1 and 7.1A. This equates to 21,289,992 shares under ASX Listing Rule 7.1 and 5,892,736 shares under ASX Listing Rule 7.1A.

Bell Potter Securities Limited acted as lead manager to the Placement.




Outlook & Product Pipeline

As part of the capital raising process the Company is pleased to provide an updated outlook on its revenue, number of product launches and store rollout targets as per the below graphs.

RHINOMED

MAKE EVERY BREATH COUNT

For more information please refer to the Capital Raising presentation lodged on the ASX on Monday 23 September 2019



RHINOMED

MAKE EVERY BREATH COUNT

For more information about Rhinomed's exciting technology, please visit www.rhinomed.global

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is commercialising applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global